Comparing remimazolam and propofol effects on heart strain during anesthesia for surgery
The Impact of Remimazolam and Propofol on the Left Ventricular Systolic Performance During Anesthesia-induction for Non-cardiac Surgery: a Speckle Tracking Analysis of the Left Ventricular Strain Using Transthoracic Echocardiography
This study is testing whether the anesthesia drug remimazolam affects heart strain differently than propofol during surgery in people who are not having heart surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Konkuk University Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05412914 on ClinicalTrials.gov |
What this trial studies
This study compares the effects of remimazolam and propofol on left ventricular global longitudinal strain (LV-GLS) during anesthesia induction for non-cardiac surgery. A total of 40 participants will be randomly assigned to receive either remimazolam or propofol. The LV-GLS will be assessed using a speckle tracking technique via transthoracic echocardiography at various time points after drug administration. The primary outcome is the lowest LV-GLS value observed after induction, with secondary outcomes including comparisons at multiple time points.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for non-cardiac surgery with a left ventricular ejection fraction greater than 50% and no regional wall motion abnormalities.
Not a fit: Patients with atrial fibrillation, unfavorable airway conditions, or those requiring inotropic support for hypotension may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify which anesthetic agent is safer for heart function during non-cardiac surgeries.
How similar studies have performed: Other studies have explored the effects of different anesthetics on cardiac function, but this specific comparison of remimazolam and propofol is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * left ventricular ejection fraction\> 50% * no left ventricular regional wall motion abnormality Exclusion Criteria: * atrial fibrillation * unfavorable airway * hypotension requiring inotropic support
Where this trial is running
Seoul
- Konkuk University Medical Center — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Tae-Yop Kim, MD, PhD — Konkuk University Medical Center
- Study coordinator: Tae-Yop Kim, MD, PhD
- Email: taeyop@gmail.com
- Phone: +82-10-8811-6942
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.